Denali Therapeutics Inc Equity-NMS: DNLI

$11.78 -1.01 (April 5, 2025)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$12.79
Open :$12.32
Today's high :$12.63
Today's low :$11.33
52W low :$11.33
52W high :$33.33
EPS(TTM): :-2.57
Shares O/S :145.22 M
Market cap :1.71 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Denali Therapeutics Inc $11.78 -0.07% - 1.71B

Frequently Asked Questions

What is the share price of Denali Therapeutics Inc today?

Denali Therapeutics Inc (DNLI) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.